Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$8.01 USD
+0.06 (0.75%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $8.00 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Earnings News For OTLK
-
Outlook Therapeutics? Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
-
Outlook Therapeutics? to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
-
Outlook Therapeutics? Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
-
Outlook Therapeutics? to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
-
Outlook Therapeutics? Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
-
Outlook Therapeutics? Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
-
Outlook Therapeutics? Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones
-
Outlook Therapeutics? Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
-
Outlook Therapeutics? Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
-
Outlook Therapeutics? Reports Financial Results for Fiscal Year 2022 and Provides Corporate Update
-
Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
-
Oncobiologics, Inc. (OTLK) May Report Negative Earnings: Know the Trend Ahead of Q3 Release